acebilustat: Clinical Trials

8 trials of acebilustat, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed. 5 Phase 2, 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 25Completed 5
Phase 13Completed 3

Follow acebilustat: new trials by email Literature Review of acebilustat trials Research Report on acebilustat

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Placebo Controlled Trial of Acebilustat (CTX 4430) for the Treatment of Human Upper Extremity Lymphedema
Acebilustat, Placebo - Lymphedema of Upper Arm
Phase 2CompletedStanford University402022-07-272026-05-28
COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Acebilustat Sub-Protocol
Acebilustat, Placebo - Covid19
Phase 2CompletedStanford University1202021-04-232023-06-13
COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol
Acebilustat, Camostat - Covid19
Phase 2CompletedStanford University1222021-04-232023-06-28
EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult Cystic Fibrosis (CF) Patients
CTX-4430, Placebo - Cystic Fibrosis
Phase 2CompletedCeltaxsys, Inc.2002015-10-302019-09-04
CTX-4430 for the Treatment of Moderate to Severe Facial Acne Vulgaris
CTX-4430, Placebo - Acne Vulgaris
Phase 2CompletedCeltaxsys, Inc.1242015-04-012016-08-02
Drug-Drug Interaction Study to Evaluate the Pharmacokinetics and Safety of CTX 4430 and Midazolam
CTX-4430, Midazolam - Healthy
Phase 1CompletedCeltaxsys, Inc.202014-09-012014-10-10
Phase 1 Study Assessing the Safety and Tolerability of CTX-4430 in Cystic Fibrosis Patients
CTX-4430, Placebo - Cystic Fibrosis
Phase 1CompletedCeltaxsys, Inc.172013-09-012015-03-06
Phase 1 Study Assessing the Safety and Tolerability of CTX-4430
CTX-4430, Mannitol, Placebo - Pulmonary Inflammation
Phase 1CompletedCeltaxsys, Inc.962012-12-012013-09-10

Conditions studied

COVID-19 (2)  ·  Cystic Fibrosis (2)  ·  Acne Vulgaris (1)  ·  Pneumonia (1)

Sponsors

Celtaxsys, Inc. (5)  ·  Stanford University (3)

Countries

United States (4)  ·  United Kingdom (3)  ·  Australia (2)  ·  Belgium (1)  ·  Canada (1)  ·  France (1)  ·  Germany (1)  ·  Italy (1)  ·  New Zealand (1)

Top investigators

Angela Rogers, MD (1)  ·  Chaitan Khosla, PhD (1)  ·  Haley Hedlin, PhD (1)  ·  J Stuart Elborn, MD, FRCP (1)  ·  Janakan Krishnarajah, MB, BS FRACP (1)  ·  Johnston Stewart, MB, BSc (1)  ·  Joseph Levitt, MD, MS (1)  ·  Lynda J Spelman, MB BS, FACD (1)  ·  Manisha Desai, PhD (1)  ·  Stanley Rockson, MD (1)  ·  Steven Rowe, MD (1)  ·  Stuart Elborn, MD (1)  ·  Upinder Singh, MD (1)  ·  Yvonne Maldonado, MD (1)

Results publications

PMID 36996150, PMID 34473343